ArticleFrontiers in medicine2026
A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acinar adenocarcinoma is the most common subtype of prostate cancer, while primary prostatic urothelial carcinoma is clinically rare. The composite tumor with both occurring simultaneously within the prostate is even rarer, with limited clinical reports and diagnostic and therapeutic experience available to date. Case presentation: This article reports a case of a 75-year-old male with concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma. The patient was admitted to the hospital due to an elevated prostate-specific antigen (PSA) level detected during physical examination for 2 years. Preoperative magnetic resonance imaging (MRI) showed a nodule in the left peripheral zone of the prostate, and radical prostatectomy was performed subsequently. Postoperative pathological diagnosis revealed prostatic acinar adenocarcinoma (Gleason score 4 + 3, pT3b stage) and primary prostatic urothelial carcinoma Conclusion: The composite tumor of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma is clinically rare. Definitive diagnosis requires comprehensive judgment based on imaging examinations, histopathological observation and immunohistochemical detection. Individualized treatment plans should be formulated based on multidisciplinary consultation, and long-term close follow-up of patients is necessary to monitor tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.